ION Breast Cancer Clinical Pathways - ION Solutions

Paraplatin (Carboplatin) VP-16 (Etoposide) EP=Moderate; FN=10%-20%Carboplatin AUC 5-6 D1Etoposide 100mg/m 2 D1-3q 21 Day Cycle>> J Clin Oncol 17:3540-3545, 1999Platinol (Cisplatin) Camptosar (Irinotecan) EP=High; FN=10%-20%Cisplatin 60mg/m 2 D1Irinotecan 60mg/m 2 D1, D8, D15q 28 Day CycleORCisplatin 30mg/m 2 D1, D8Irinotecan 65mg/m 2 D1, D8q 21 Day Cycle>> N Engl J Med 346:85-91, 2002>> J Clin Oncol 24:2038-2043, 2006Taxol (Paclitaxel) EP=Low, FN=10%-20%Paclitaxel 175mg/m 2 D1 (or weekly equivalent)q 21 Day Cycle>> Br J Cancer 77:347-351, 1998>> Anticancer Res 26:777-781, 2006Taxotere (Docetaxel) EP=Low; FN=10%-20%Docetaxel 100mg/m 2 D1 (or weekly equivalent)q 21 Day Cycle>> Eur J Cancer 30A:1058-1060, 1994Camptosar (Irinotecan) EP=Moderate; FN> J Clin Oncol 10:1225-1229, 1992Hycamtin (Topotecan) EP=Low; FN˃20%Topotecan 2.3mg/m 2 PO D1-5ORTopotecan 1.5mg/m 2 D1-5q 21 Day CycleORTopotecan 4mg/m 2 D1, D8, D15q 28 Day Cycle>> J Clin Oncol 17:658-667, 1999>> J Clin Oncol 24:5441-5447, 2006>> J Clin Oncol 25:2086-2092, 2007Gemzar (Gemcitabine) EP=Low; FN> J Clin Oncol 21:1550-1555, 2003>> Ann Oncol 12:557-561, 2001Page 34 of 39© 2013 by ION Solutions. All rights reserved